146 related articles for article (PubMed ID: 24300041)
21. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
Petrella LA; Sambol SP; Cheknis A; Nagaro K; Kean Y; Sears PS; Babakhani F; Johnson S; Gerding DN
Clin Infect Dis; 2012 Aug; 55(3):351-7. PubMed ID: 22523271
[TBL] [Abstract][Full Text] [Related]
22. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Hardesty JS; Juang P
Pharmacotherapy; 2011 Sep; 31(9):877-86. PubMed ID: 21923589
[TBL] [Abstract][Full Text] [Related]
23. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
[TBL] [Abstract][Full Text] [Related]
24. Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections.
Soriano MM; Liao S; Danziger LH
Expert Rev Anti Infect Ther; 2013 Aug; 11(8):767-76. PubMed ID: 23977933
[TBL] [Abstract][Full Text] [Related]
25. Fidaxomicin failures in recurrent Clostridium difficile infection: a problem of timing.
Orenstein R
Clin Infect Dis; 2012 Aug; 55(4):613-4. PubMed ID: 22610922
[No Abstract] [Full Text] [Related]
26. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
27. Fidaxomicin for Clostridium difficile infection.
Linsky A; Gupta K; Hermos JA
N Engl J Med; 2011 May; 364(19):1875; author reply 1875-6. PubMed ID: 21561361
[No Abstract] [Full Text] [Related]
28. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
29. Fidaxomicin for Clostridium difficile Infection.
Safdar N; Craig WA
N Engl J Med; 2011 May; 364(19):1875; author reply 1875-6. PubMed ID: 21561360
[No Abstract] [Full Text] [Related]
30. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
[TBL] [Abstract][Full Text] [Related]
31. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.
Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ
Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999
[TBL] [Abstract][Full Text] [Related]
32. A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences.
Skinner AM; Tan X; Sirbu BD; Danziger LH; Gerding DN; Johnson S
Clin Infect Dis; 2021 Sep; 73(6):1107-1109. PubMed ID: 33714998
[TBL] [Abstract][Full Text] [Related]
33. Fidaxomicin therapy in critically ill patients with Clostridium difficile infection.
Penziner S; Dubrovskaya Y; Press R; Safdar A
Antimicrob Agents Chemother; 2015 Mar; 59(3):1776-81. PubMed ID: 25534722
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies.
Chen LF; Anderson DJ
Future Microbiol; 2012 Jun; 7(6):677-83. PubMed ID: 22702523
[TBL] [Abstract][Full Text] [Related]
35. Successful Fidaxomicin Hospital Discharges of Adult Patients With Clostridioides difficile Infections Post-2021 Guidelines: Are Economic Barriers Finally Coming Down?
Fang N; Ha D; Dong K; Leung T; Lee S; Holubar M; Meng L
Clin Infect Dis; 2022 Aug; 75(3):519-521. PubMed ID: 34971358
[TBL] [Abstract][Full Text] [Related]
36. Fidaxomicin: balancing evidence and economics.
Stevens V; Onufrak N; Brown J
Am J Health Syst Pharm; 2012 Jun; 69(11):931. PubMed ID: 22610024
[No Abstract] [Full Text] [Related]
37. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
Crook DW; Walker AS; Kean Y; Weiss K; Cornely OA; Miller MA; Esposito R; Louie TJ; Stoesser NE; Young BC; Angus BJ; Gorbach SL; Peto TE;
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S93-103. PubMed ID: 22752871
[TBL] [Abstract][Full Text] [Related]
38. Fidaxomicin for the treatment of Clostridium difficile infections.
Whitman CB; Czosnowski QA
Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
[TBL] [Abstract][Full Text] [Related]
39. Clostridioides difficile from intracardiac vegetation.
Chaudhry R; Khullar S; Arif N; Sagar T; Meena D; Kumar Chowdhury U
Anaerobe; 2021 Jun; 69():102350. PubMed ID: 33610766
[TBL] [Abstract][Full Text] [Related]
40. Review: NAATs diagnose C difficile; vancomycin improves cure, and fidaxomicin reduces recurrence.
Zar FA
Ann Intern Med; 2016 Jul; 165(2):JC4. PubMed ID: 27429316
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
